CSA Medical, Inc. Secures $10 Million in Series A Financing
"The Series A Financing eliminated all debt and brings the total investment in our novel, energy-based spray cryotherapy system to $32 million to date," said Bill Floyd, president & CEO of CSA Medical. "This funding will support our efforts to address customer demand as we launch and seek expanded clinical indications for our new platform technology, the truFreeze® system.
Cryotherapy, the destruction of tissue by freezing, is a well-established approach to treatment in many branches of surgery. CSA Medical's spray cryotherapy system is already in use for treating esophageal disease at nearly 80 top-ranked cancer centers and academic teaching hospitals throughout the United States. Nearly 7,000 spray cryotherapy treatments have been performed to date.
About CSA Medical
CSA Medical, Inc. develops and manufactures a proprietary therapeutic interventional platform, the CryoSpray Ablation System, comprised of a device, specialty catheters and agent that allow delivery of therapeutic doses of a cryogen to flash freeze and destroy diseased tissue inside the body. The Company is the first to harness the power of extreme cold (-196 C) liquid nitrogen therapeutic energy delivery inside the body. To learn more, please visit www.CSAmedical.com.
SOURCE CSA Medical, Inc.